Amylin Resale Registration Statement Declared Effective by SEC
August 07 2007 - 5:54PM
PR Newswire (US)
SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) today announced that on August 7, 2007, it filed
with the Securities and Exchange Commission (the "SEC") a resale
registration statement on Form S-3 (the "Registration Statement")
that was effective immediately upon filing with the SEC. Amylin
filed the Registration Statement to satisfy certain of its
obligations under a registration rights agreement that Amylin
entered into in connection with its recent private placement of
$575 million in aggregate principal amount of 3.0% convertible
senior notes due 2014. The Registration Statement, while effective,
allows selling securityholders to publicly resell the convertible
senior notes and the common stock issuable upon their conversion,
subject to certain limitations included in the registration rights
agreement and the satisfaction by selling securityholders of the
prospectus delivery requirements of the Securities Act of 1933, as
amended (the "Securities Act"), in connection with any such
resales. A written prospectus meeting the requirements of Section
10 of the Securities Act may be obtained from Amylin at 9360 Towne
Centre Drive, San Diego, California 92121, Attention: General
Counsel. This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934, as amended. In
particular, selling securityholders may only use the resale
registration statement for resales of their securities while it
remains effective and subject to the satisfaction of certain other
conditions. About Amylin Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide
acetate) injection and BYETTA(R) (exenatide) injection. Amylin's
research and development activities leverage the company's
expertise in metabolism to develop potential therapies to treat
diabetes and obesity. Amylin is located in San Diego, California
with over 1,700 employees nationwide. Further information on Amylin
Pharmaceuticals and its pipeline in metabolism is available at
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Mark G. Foletta, Senior Vice President of Finance and
Chief Financial Officer of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024